Login

Financial Snapshot

Revenue
TTM
$27.03M
Gross Margin
TTM
88.02%
Net Income
TTM
-$3.233M
Current Assets
2025 Q3
$11.02M
Current Liabilities
2025 Q3
$2.962M
Current Ratio
2025 Q3
372.18%
Total Assets
2025 Q3
$11.12M
Total Liabilities
2025 Q3
$7.263M
Book Value
2025 Q3
3.854M
Cash
2025 Q3
$7.270M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
$558.0K

Stock Price

Loading...
Market Cap: $29.962 Million

About

InnoCan Pharma Corp. operates as a pharmaceutical tech company. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

Industry: Pharmaceutical Preparations

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support